HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Negative 68.1%

Neg 68.1% Neu 0% Pos 0%

HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $30 to $26.